GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Immunogen, Inc. (IMGN) [hlAlert]

Rating:
Outperform
IMGN
up 200.00 %

Immunogen, Inc. (IMGN) rated Outperform with price target $16 by RBC Capital Mkts

Posted on: Friday,  Apr 8, 2011  8:25 AM ET by RBC Capital Mkts

RBC Capital Mkts rated Outperform Immunogen, Inc. (NASDAQ: IMGN) on 04/08/2011. Previously RBC Capital Mkts rated Buy Immunogen, Inc. (NASDAQ: IMGN) on
10/15/2007., when the stock price was $4.76. Since then, Immunogen, Inc. has gained 200.00% as of 01/08/2016's recent price of $14.28.
If you would have followed the previous RBC Capital Mkts's recommendation on IMGN, you would have gained 200% of your investment in 3007 days.

ImmunoGen, Inc. develops pharmaceuticals, primarily for the treatment of cancer. The company's product candidates are called tumor-activated prodrugs and are based on its proprietary immunoconjugate technology platform. Unlike conventional chemotherapeutic agents, tumor-activated prodrugs are intended to deliver potent chemotherapy specifically to a tumor. Each tumor-activated drug immunoconjugate comprises a small-molecule drug which has been chemically linked to a monoclonal antibody.

RBC Capital Markets is an international corporate and investment bank that provides innovative solutions and a focused set of products and services to institutions, corporations, governments and high net worth clients around the world. With nearly 3,700 professional and support staff, we operate out of 75 offices in 15 countries and deliver our products and services through operations in Asia and Australasia, the UK and Europe and in every major North American city.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
4/8/2011 8:25 AM Buy
None
12.15 16.00
as of 12/30/2011
1 Week down  -4.61 %
1 Month down  -4.69 %
3 Months up  5.65 %
1 YTD up  25.05 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/15/2007 9:25 AM Buy
None
4.76

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy